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Abstract
Background: Loss of skeletal muscle mass and function in humans is associated with significant morbidity and mortality.
The role of myostatin as a key negative regulator of skeletal muscle mass and function has supported the concept that
inactivation of myostatin could be a useful approach for treating muscle wasting diseases.
Methods: We generated a myostatin monoclonal blocking antibody (REGN1033) and characterized its effects in vitro
using surface plasmon resonance biacore and cell-based Smad2/3 signaling assays. REGN1033 was tested in mice for
the ability to induce skeletal muscle hypertrophy and prevent atrophy induced by immobilization, hindlimb suspension,
or dexamethasone. The effect of REGN1033 on exercise training was tested in aged mice. Messenger RNA sequencing,
immunohistochemistry, and ex vivo force measurements were performed on skeletal muscle samples from
REGN1033-treated mice.
Results: The human monoclonal antibody REGN1033 is a specific and potent myostatin antagonist. Chronic treatment
of mice with REGN1033 increased muscle fiber size, muscle mass, and force production. REGN1033 prevented the loss of
muscle mass induced by immobilization, glucocorticoid treatment, or hindlimb unweighting and increased the gain of
muscle mass during recovery from pre-existing atrophy. In aged mice, REGN1033 increased muscle mass and strength
and improved physical performance during treadmill exercise.
Conclusions: We show that specific myostatin antagonism with the human antibody REGN1033 enhanced muscle mass
and function in young and aged mice and had beneficial effects in models of skeletal muscle atrophy.
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Background
Diminished muscle function caused by decreased muscle
mass and strength is a key feature of several diseases and
disabling conditions and is associated with injury, surgery,
frailty, metabolic disorders, and catabolic illnesses such as
cancer, heart failure, and chronic lung disease [1, 2]. In the
elderly, recovery from orthopedic interventions after a fra-
gility hip fracture for example is significantly impacted by
the occurrence of rapid muscle wasting and development
of weakness [3]. Therefore, it is essential to develop therap-
ies that increase muscle strength, improve physical per-
formance, and for certain indications, increase survival.
Myostatin plays a central role in the development and
maintenance of skeletal muscle, acting as a negative regula-
tor of muscle mass [4, 5]. It is a secreted ligand belonging
to the transforming growth factor-β superfamily of growth
and differentiation factors and is unique among this family
in its specific skeletal muscle expression [4]. Inactivating
mutations of the myostatin gene have been described in
cattle, sheep, dogs, and humans and result in a profound
increase in skeletal muscle mass, without obvious negative
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effects [6–10]. Targeted deletion of the myostatin gene in
mice (Mstn−/−) reproduces the hypermuscular pheno-
type and results mainly from muscle fiber hyperplasia
and also from hypertrophy [4]. Mstn−/− mice also dis-
play significant metabolic improvements including re-
duced adiposity, increased insulin sensitivity, and
resistance to obesity [11–13].
Myostatin is synthesized as a precursor protein, and fol-
lowing processing, mature myostatin is released as a 24-
kDa covalent homodimer with its propeptide remaining
non-covalently bound, forming an inactive latent complex
[5]. Unprocessed precursor and latent complex circulate
in the serum [4]. Active myostatin can be released from
latent complex by subsequent propeptide cleavage. In
serum, myostatin is found in complex with inhibitory pro-
teins, including follistatin, follistatin-like 3, and growth
and differentiation factor-associated serum protein-1
(GASP-1) [14, 15]. Myostatin mediates its biological effects
primarily through the activin receptor IIB (ActRIIB), which
then recruits activin-like kinase-4 (ALK-4) or ALK-5, lead-
ing to phosphorylation and activation of the cytoplasmic
receptor-regulated Smad2 and 3, which translocate to the
nucleus to induce specific gene changes [4, 16].
In this study, we report on the characterization of
REGN1033, a fully human monoclonal antibody that in-
hibits myostatin with sub-nanomolar affinity and high
specificity. We demonstrate the efficacy of REGN1033 in
increasing muscle mass, strength, and function in both
young and aged mice and in models of muscle atrophy,
including prevention of disuse atrophy as well as in re-
covery from pre-existing atrophy. REGN1033 is cur-
rently in phase 2 clinical development.
Methods
Antibodies and protein reagents
REGN1033 is a fully human monoclonal antibody specific
to myostatin derived by immunizing with the mature hu-
man myostatin using Regeneron’s VelocImmune® mice
[17, 18] in which the myostatin gene was also homozy-
gously ablated, so as to decrease immunotolerance to this
protein. The selected anti-myostatin antibody contains an
IgG4 constant region. Soluble human ActRIIB-hFc
(ActRIIB-hFc) was produced in Chinese hamster ovary
(CHO) cells and contains the extracellular domain (1-133)
of the human ActRIIB receptor (ACVR2B) made as an in-
frame fusion with human IgG1 Fc-domain. A second
human monoclonal antibody (REGN647) which was
shown to be specific for myostatin in binding and bio-
assay studies was used for immunoblotting; to visualize
myostatin propeptide, an anti-propeptide sheep poly-
clonal antibody (AF1539; R&D Systems: Minneapolis,
MN) was used. Human myostatin, growth and differen-
tiation factor 11 (GDF11), and activin A were purchased
from R&D Systems.
Surface plasmon resonance
The affinities of REGN1033 and ActRIIB-hFc for human
myostatin, GDF11, and activin A were measured in surface
plasmon resonance biacore experiments performed on a
Biacore T200 instrument (GE Healthcare, Pittsburgh, PA)
using a dextran-coated (CM5) chip at 25 °C. The running
buffer was filtered HEPES-buffered Steinberg’s solution
(HBS-T) containing 10 mM HEPES, 150 mM NaCl, 3 mM
ethylenediaminetetraacetic acid (EDTA), 0.05 % (v/v) Sur-
factant P20, 10 mg/ml carboxymethyldextran sodium salt,
and 0.5 mg/ml bovine serum albumin (pH 7.4). A capture
sensor surface was prepared by covalently immobilizing
goat anti-human Fcγ antibody (Jackson ImmunoResearch,
West Grove, PA) to the chip surface using 1 ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride/N-
hydroxysuccinimide (EDC/NHS) coupling chemistry.
Following surface activation, anti-human Fc antibody
in 0.1 M acetate buffer (pH 4.5) was injected over the
activated chip surface until a resonance unit (RU) sig-
nal of about 4000 RU (anti-human Fc antibody) was
reached. The activated coupled chip surfaces were then
washed and treated with 10 mM glycine-HCl (pH 1.5)
to remove uncoupled residual proteins. REGN1033 and
ActRIIB-hFc were captured through their Fc regions
between 32 and 39 RU by an anti-human Fc antibody
immobilized on the sensor chips and were tested for
binding to the human myostatin, GDF11, and activin A.
Myostatin, GDF11, and activin A proteins were prepared
at concentrations between 40 and 0.78 nM and individu-
ally injected over captured REGN1033 or ActRIIB-hFc
surface. All capture surfaces were regenerated with one
30-s pulse of 10 mM glycine-HCl (pH 1.5). Kinetic param-
eters were obtained by globally fitting the data to a 1:1
binding model using Biacore T200 Evaluation Software.
The equilibrium dissociation constant (KD) was calculated
by dividing the dissociation rate constant (kd) by the asso-
ciation rate constant (ka).
Smad2/3 cell-based activity assay
A cell-based assay for determining Smad2/3 activation
was established in A204 cells stably expressing Smad-
dependent (CAGA12) luciferase. Ligands were serially
diluted and added to 20,000 A204/Smad2/3/Luc cells
per well plated in McCoy’s 5A medium supplemented
with 10 % fetal calf serum (FCS)/G418 to generate a
dose-response curve. Inhibition of ligand-mediated
ActRIIB signaling by REGN1033, ActRIIB-hFc, or con-
trol antibody was tested by serially diluting the anti-
bodies or soluble receptor and incubating with a
constant concentration of 1 nM myostatin, 0.4 nM
GDF11, or 0.4 nM activin A and cells for 6 h at 37 °C.
Luminescence was measured using One Glo (Promega,
Madison, WI).
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Human myoblast treatment and immunoblot analysis
Human skeletal myoblasts (Lonza Group Ltd, Anaheim,
CA) were cultured in complete growth media (Lonza).
Cells (6 × 105 per well in a six-well plate) were cultured
for 24 h, and serum starved for 4 h before treated with
myostatin, GDF-11, or activin A at 4 nM in presence of
40 nM of REGN1033 or ActRIIB-hFc for 30 min. Cells
were lysed in NP-40 buffer containing 1 % NP-40,
100 mM KCL, 20 mM Tris/HCL (pH 7.6), 1 mM EGTA,
and 1 mM NaF with various protease and phosphatase in-
hibitors and cleared by centrifugation. Soluble fractions
were separated in 4–20 % Invitrogen Precast Tris-Glycine
gels using SDS-PAGE followed by transfer to polyvinyli-
dene fluoride (PVDF) membranes. Total levels of Smad2/
3 and phosphorylated Smad2 were determined with rabbit
anti-Smad2/3 and phospho-Smad2 (Ser465/467) anti-
bodies (Cell Signaling Technology, Danvers, MA).
Immunoblot analysis of mouse serum following
REGN1033 administration
Serum was collected following 4-week treatment of male
CB17-severe combined immunodeficiency (SCID) mice
with REGN1033 or control antibody (10 mg/kg by sub-
cutaneous (s.c.) dosing; twice in the first week and once
a week for three weeks). Serum (60 μl per mouse) was
diluted tenfold in phosphate-buffered saline (PBS) con-
taining 0.2 % Nonidet P-40 and 1X protease and phos-
phatase inhibitors. Immune complexes were captured
with Protein A-Sepharose beads and eluted with non-
reducing SDS-PAGE buffer. The equivalent of 2.4 μl of
serum was then run on a 4–20 % gradient Tris-glycine
gel and immunoblotted with a monoclonal antibody
against mature myostatin, produced at Regeneron, or
with a myostatin propeptide polyclonal antibody. CHO
cells stably expressing furin protease were transiently
transfected with an expression plasmid encoding human
myostatin precursor, and conditioned media was col-
lected after three days; 5 μl was loaded onto the gel to
serve as a positive control. To demonstrate myostatin
antibody specificity, 2 μl of serum from wild-type and
Mstn−/− mice was probed by immunoblot.
Animal studies
Mice (Taconic, Hudson, NY) were housed four to five
per cage in a controlled environment (12-h light/dark
cycle, 23 ± 1 °C, 60–70 % humidity) and fed ad libitum
with standard chow (Purina Laboratory Rodent Diet
5001, LabDiet, St. Louis, MO). All animal studies were
conducted in accordance with the Regeneron Pharma-
ceuticals Institutional Animal Care and Use Committee.
Muscle hypertrophy studies
The effect of REGN1033 on muscle mass was determined
after 4-week treatment of varying doses of REGN1033
(0.1–30 mg/kg) or control antibody (30 mg/kg) in 9-week-
old male CB17-SCID mice (n = 5/group). Animals were
grouped by body weight and dosed via s.c. injection twice
the first week and once a week for the following 3 weeks.
At the end of the fourth week, tibialis anterior (TA) and
gastrocnemius (GA) complex muscle groups were har-
vested and weighed.
Ex vivo force measurements
REGN1033 or control antibody (10 mg/kg) was adminis-
tered to C57BL/6 male mice (n = 6/group) twice a week
for 3 weeks via s.c. injection. At the end of 3 weeks of
treatment, ex vivo force measurements of the TA muscle
were obtained. Briefly, mice were anesthetized under iso-
flurane (4.5 %), and the right TA muscle was excised by
cutting the femur just proximal to the femoral head
above the knee and the tibia and fibula proximal to the
ankle. The muscle was then placed in an oxygenated
bath containing Krebs solution with 10 mM glucose at
27 °C. The femoral head was secured to a stanchion
while the distal tendon was tied to the arm of a 305C
Muscle Lever System (Aurora Scientific, Aurora, ON,
Canada). Optimal length was achieved by increasing the
length of the muscle by small increments followed by a
single 1-Hz stimulation until a maximum twitch force
was achieved. Maximal isometric tetanic force was then
determined by stimulating each muscle at 10-Hz inter-
vals (from 40 to 100 Hz) with 90-s rest periods prior to
each stimulation.
Casting immobilization
Two groups of 12-week-old C57BL/6 male mice (n = 5/
group) were anesthetized, and the right ankle joint was
immobilized at a 90° angle with casting material for
14 days. During immobilization, mice were injected sub-
cutaneously twice a week with 30 mg/kg of REGN1033 or
control antibody. GA muscle weights were compared to a
separate, age-matched, non-immobilized group treated
with control antibody (30 mg/kg).
Dexamethasone-induced atrophy
Dexamethasone was administered at a rate of 23.0 μg/day
by micro-osmotic pump (DURECT Corporation, Cuper-
tino, CA) for 2 weeks in 11-week-old C57BL/6 male mice
(n = 5/group). During dexamethasone treatment, animals
were given either 10 mg/kg of REGN1033 or isotype con-
trol antibody by s.c. injection twice a week. A separate
group, implanted with osmotic pumps delivering saline
and given 10 mg/kg of control antibody, served as a nega-
tive control. At the end of 2 weeks, TA and GA muscles
were collected and weighed.
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Hindlimb suspension
Prevention of hindlimb suspension (HLS)-induced atrophy
was assessed in 10-week-old C57BL/6 male mice (n = 8/
group). Sixteen mice were tail-suspended for 7 days to pre-
vent weight bearing by the hind limbs; forelimbs were
unaffected. Mice were housed in special cages (Techshot
Inc., Greenville, IN) with free access to food and water. An-
other group of mice was left unperturbed to serve as
negative controls. Animals were treated with 10 mg/kg
of REGN1033 or control antibody by s.c. injection
2 days prior to HLS, on the day of HLS, and 4 days into
HLS. At the end of 7 days, muscles were collected,
weighed, and stored for further analysis. Similarly, the
effect of REGN1033 during recovery from 7 days of
HLS-induced atrophy was examined in 11-month-old
C57BL/6 male mice (n = 6/group). A total of eighteen
mice were suspended for 7 days, and an unperturbed
group was included in the study as a negative control. On
day 7 of HLS, the animals were released from suspension
and randomized into three groups based on body weight
loss. TA and GA muscles were collected and weighed
from one HLS group and the unperturbed control group.
The remaining HLS animals were allowed to recover for
1 week, receiving either REGN1033 or control antibody at
10 mg/kg twice a week during recovery, at which time TA
and GA muscles were collected and weighed.
Running endurance in aged mice
Male C57BL/6 at 19 months of age were randomized into
four groups (n = 6-8/group): a sedentary or exercise group
receiving either REGN1033 or control antibody. All mice
were dosed via s.c. injection twice per week for 3 weeks at
10 mg/kg. During treatment, mice in the exercise group
were placed on an exercise regimen involving one training
session a day, consisting of 20 min on an Exer 6 M tread-
mill (Columbus Instruments, Columbus, OH) at 10 m/min
with a 5° incline, 5 days a week for three consecutive
weeks. At the end of 3 weeks of treatment, endurance was
measured in all four groups using a treadmill exhaustion
test. Briefly, mice ran on a treadmill at 10 m/min with a 5°
incline for 4 min, and the speed was increased by 2 m/min
every subsequent 4 min until 16 m/min was reached. At
30 min, the speed was increased to 18 m/min and this
speed was maintained until the mice reached exhaustion.
Exhaustion was defined as the inability of the mouse to re-
main on the treadmill despite mechanical prodding and an
electrical shock stimulus.
Histology
Ten-week-old male SCID mice were treated with s.c. injec-
tion of REGN1033 or control antibody for 4 weeks
(10 mg/kg; n = 6/group). TA muscles were collected and
sectioned, and muscle fibers were stained for laminin with
polyclonal rabbit anti-LAMA1 antibody (Sigma-Aldrich,
St. Louis, MO). Fiber cross-sectional area was measured
using MetaMorph software (Molecular Devices, Sunnyvale,
CA). Fiber types were measured in sections of GA muscle
that were dried and washed with PBS, quenched in metha-
nol and 1 % H2O2 solution, blocked with 4 % goat serum
and 1 % BSA, and incubated with the following primary
antibodies overnight at 4 °C; (1) laminin (1:2000; Sigma),
(2) myosin heavy chain slow (1:400; Novocastra, Leica
Microsystems Inc., Buffalo Grove, IL), (3) myosin heavy
chain 2A (1:500; DSHB, Iowa City, IA), and (4) myosin
heavy chain 2B (1:500; DSHB, Iowa City, IA). After a PBS
wash, the slides are incubated with the following second-
ary antibodies from Vector Laboratories (Burlingame,
CA); (1) biotinylated goat α-rabbit IgG (1:1200), (2)
biotinylated goat α-mouse IgG (1:1000), and (3) biotinyl-
ated goat α-mouse IgM (1:1000) for 1 h at 21 °C followed
by detection with the ABC kit (1:500; Vector Laborator-
ies). After diaminobenzidine (DAB)/peroxidase brown vi-
sualized reaction (0.4 mg/ml DAB, 0.0003 % H2O2), slides
were scanned by the Aperio Scanscope AT. Images were
analyzed by HALO software (Indica Labs, Corrales, NM).
RNA sequencing
Messenger RNA was prepared, sequenced, and analyzed
as previously described [19].
Statistical analysis
Data are presented as mean ± standard error, and values
of P < 0.05 were considered statistically significant. Stat-
istical significance was measured through unpaired, two-
tailed Student’s t test for comparisons between two
groups, one-way or two-way ANOVA with Tukey’s post
hoc analysis for studies with group of three or more or
two-way repeated measures ANOVA with Bonferroni’s
post hoc analysis for studies where time was a factor
using Prism software (GraphPad Software).
Results
In vitro characterization of REGN1033 anti-myostatin
antibody
REGN1033 was selected to have high affinity to myosta-
tin (KD = 24 pM) (Table 1). This applies to mouse, rat,
monkey, and human since myostatin is 100 % conserved
across these species. No binding was detected between
REGN1033 and human GDF11 or activin A. ActRIIB-
hFc exhibited high affinity binding to GDF11 and activin
A with KD values comparable to those measured for
myostatin (KD = 14-87 pM) (Table 1).
In the A204 cell-based bioassay, myostatin, GDF11, or
activin A stimulated Smad2/3 signaling with 50 % of the
maximum activity (EC50) at 1.37 nM for myostatin,
0.34 nM for GDF11, and 0.09 nM for activin A (Fig. 1a).
REGN1033 effectively blocked receptor activation by a con-
stant concentration of 1 nM myostatin (IC50 = 0.73 nM)
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but not by constant concentrations of 0.4 nM GDF11 or
activin A (Fig. 1b–d). ActRIIB-hFc blocked receptor activa-
tion caused by all three ligands (myostatin; IC50 = 0.57 nM,
GDF11; IC50 = 0.46 nM, and activin A; IC50 = 1.2 nM)
(Fig. 1b–d).
Consistent with the above data, we found that myosta-
tin, GDF11, and activin A increased phosphorylated
Smad2 (p-Smad2) levels in lysates from human primary
skeletal myoblast (Fig. 1e). REGN1033 selectively reduced
p-Smad2 levels induced by myostatin, whereas ActRIIB-
hFc blocked Smad2 activation by all three ligands (Fig. 1e).
These data show that REGN1033 binds myostatin with
sub-nanomolar affinity and high specificity and blocks
myostatin-induced Smad2/3 signaling.
REGN1033 increases muscle hypertrophy and force in
mice
The effect of REGN1033 on skeletal muscle mass was de-
termined in CB17-SCID male mice following 28 days of
treatment with REGN1033 (0.1, 0.75, 2.5, 10, or 30 mg/kg)
or control antibody (10 mg/kg). Figure 2a shows GA
muscle weights normalized to body weights at the start of
the experiment and depicted as the percent change com-
pared to control. Body weights increased 3–7 % in the
REGN1033-treated animals relative to the control group
(data not shown). REGN1033 elicited significant increase
in muscle weights at 2.5 mg/kg and higher doses, produ-
cing GA muscle weight increases of 19–25 % (Fig. 2a).
Aggregate data from 17 studies revealed that treatment
with 10 mg/kg of REGN1033 for 3–4 weeks increased GA
muscle weight by 20.8 ± 0.6 % (P < 0.0001). REGN1033
produced a similar increase in TA muscle weight from
CB17-SCID mice (18.9 ± 1.3 %; P < 0.0001) (Fig. 2b). Com-
parable increases in GA and TA muscles was observed in
REGN1033 treated C57BL/6 mice (Fig. 2b). Heart weight
did not significantly changed with REGN1033 treatment in
either strain of mice (Fig. 2c).
To assess the effects of REGN1033 on muscle fiber
area and number, CB17-SCID mice were administered
REGN1033 or control antibody (10 mg/kg) for 4 weeks
and the TA muscle was removed for histological analysis
(Fig. 2d). Comparison of the frequency distribution of
muscle fiber cross-sectional area showed a shift towards
higher fiber diameter (Fig. 2e). On average, data from five
independent studies showed that REGN1033 increased
muscle fiber area by 15.4 ± 3.1 % (P < 0.001; n = 26) rela-
tive to control antibody-treated animals. Muscle fiber
number and type did not change (Fig. 2f, g).
In a separate study, C57BL/6 mice were treated with
REGN1033 or control antibody (10 mg/kg) for 3 weeks
and TA muscle was isolated for ex vivo isometric force
measurements. Figure 2h shows that REGN1033 increased
isometric force production at all stimulation frequencies.
Maximal tetanic force was increased by 16.7 % (P < 0.05,
n = 6) compared to force measured in muscle from control
antibody-treated mice (Fig. 2i). Specific force generation
remained unchanged between muscle from control anti-
body and REGN1033-treated mice (Fig. 2j). These data
show that REGN1033-induced muscle hypertrophy trans-
lates into an increase in muscle fiber cross-sectional area
and force.
REGN1033 binds mature myostatin, latent complex, and
pro-myostatin
Myostatin in circulation exists primarily as a latent
complex consisting of the mature homodimer bound
non-covalently by its propeptide; unprocessed dimeric
pro-myostatin and an apparently partially processed
form are also seen [5]. To see if REGN1033 forms stable
complexes with myostatin in vivo, we performed pull-down
assays. Immunoblot analysis of Protein A-Sepharose pre-
cipitates of serum samples from REGN1033 or control
antibody-treated mice (10 mg/kg; 28 days) with an antibody
against mature myostatin demonstrates that REGN1033
binds (1) mature myostatin (~22 kDa), (2) unprocessed pre-
cursor (~100 kDa), and (3) partially processed latent com-
plex (~50 kDa); a faint band migrating at the expected
molecular weight of myostatin monomer (~12 kDa) was
also detected (Fig. 3a). None of these species were present
in serum samples from mice-injected with control anti-
body. These myostatin forms are also present in the posi-
tive control lane obtained from myostatin-transfected CHO
cells (Fig. 3a). A separate propeptide-specific immunoblot
of the same samples demonstrates the ability of REGN1033
to bind myostatin when it is bound in a latent complex
with its prodomain, i.e., the prodomain is specifically co-
immunoprecipitated along with mature myostatin (Fig. 3b).
To demonstrate specificity of the myostatin immunoblot-
ting antibody, the antibody was used to probe serum from
wild-type (WT) and Mstn−/− mice (KO) (Fig. 3c); myostatin
precursor, mature homodimer, and partially processed
forms are seen in the WT sample and are absent from the
myostatin KO sample.
Table 1 Kinetic binding parameters for REGN1033 and ActRIIB-hFc




Ligand Kinetic binding parameters
ka (M
−1s−1) kd (s
−1) KD (pM) T1/2 (min)
REGN1033 GDF8 1.23 × 106 2.93 × 10−5 23.9 394
GDF11 NB NB NB NB
Activin A NB NB NB NB
ActRIIB-hFc GDF8 5.98 × 106 1.00 × 10−4 16.8 115
GDF11 7.38 × 106 1.03 × 10−4 14.0 112
Activin A 9.17 × 105 7.94 × 10−5 86.6 146
NB no detectable binding
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Gene expression analysis in muscle from REGN1033-
treated mice
We analyzed mRNA levels of genes expressed in GA
muscle from CB17-SCID and C57BL/6 mice treated with
REGN1033 or control antibody (10 mg/kg) for 3 to
4 weeks. Surprisingly, a total of only eight genes showed a
change in relative mRNA levels of ≥twofold (P < 0.01) in
response to REGN1033 treatment (Fig. 4). mRNA level of
one gene was upregulated (Actc1), whereas the levels of
two genes were reduced (Dkk3 and Zmynd17) in both
strains of mice. Expression levels of three genes (Mybph,
Tph1, and 4832428D23Rik) were specifically upregulated
in CB17-SCID mice (Fig. 4a). The mRNA level of Fam65b
was increased, whereas expression of Igfn1 was reduced in
C57BL/6 mice (Fig. 4b).
REGN1033 prevents muscle atrophy and spares muscle
force
To determine if REGN1033 prevents skeletal muscle at-
rophy, we performed studies in models of atrophy
induced by casting immobilization or dexamethasone
administration. Hindlimb casting for 2 weeks reduced
GA muscle mass by −24.3 ± 4.9 % (P < 0.01, n = 5) com-
pared to non-immobilized limb receiving control anti-
body (Fig. 5a). In contrast, immobilized mice treated
with REGN1033 showed an increase in GA muscle
Fig. 1 Effects of myostatin, GDF11, and activin A on Smad2/3 activity. a Smad2/3 activity was recorded as relative luminescence units (RLU) from
A204/Smad2/3/Luc reporter cells in the presence of increasing concentrations of myostatin, GDF11, or activin A. Smad2/3 activity in the presence
of constant myostatin (b), GDF11 (c), or activin A (d) concentrations and increasing concentrations of control antibody (circles), REGN1033 (squares),
and ActR2B-hFc (triangles). e Phospho-Smad2 (p-Smad2) and total Smad2/3 western blot from human skeletal myoblasts in the absence and presence
of myostatin, GDF11, or activin A and either control antibody (Control mAb), ActRIIB-hFc, or REGN1033
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mass by 3.9 ± 6.0 % (n = 5) over GA muscle from non-
immobilized control antibody-treated mice. This repre-
sents a complete prevention of muscle loss by
REGN1033.
The ability of REGN1033 to prevent muscle wasting
was also examined in glucocorticoid-induced atrophy
(Fig. 5b). In the presence of control antibody, 2-week
treatment of C57BL/6 mice with dexamethasone-
induced muscle atrophy as measured by the loss of
TA (−17.2 ± 1.2 %; P < 0.001, n = 5) or GA (−16.2 ±
1.0 %; P < 0.0001, n = 5) muscle mass. In contrast,
REGN1033 (10 mg/kg) prevented the loss of muscle mass
induced by dexamethasone in both muscle types (Fig. 5b).
Importantly, ex vivo force analysis of the TA muscle dem-
onstrated that the atrophy seen was accompanied by loss
of isometric force production and that this functional loss
was alleviated by REGN1033 (10 mg/kg; Fig. 5c). Maximal
tetanic force was reduced by −15.0 % by dexamethasone
Fig. 2 Effects of REGN1033 on muscle mass, muscle fiber area, and number and force. a Gastrocnemius anterior (GA) muscle weight after 4 weeks of
treatment with REGN1033 at 0.1, 0.75, 2.5, 10, or 30 mg/kg in CB17-SCID mice. Irrelevant isotype antibody was used as control. Muscle weights were
normalized by starting body weights and expressed as percent changes from isotype control. b GA and tibialis anterior (TA) muscle weights normalized
by starting body weight and expressed as percent changes from isotype control in CB17-SCID and C57BL/6 mice dosed at 10 mg/kg for 3–4 weeks.
c Heart weights normalized by starting body weight and expressed as percent changes from isotype control in CB17-SCID mice dosed at 10 mg/kg for
4 weeks. d H&E staining of TA muscle from isotype control antibody and REGN1033-treated CB17-SCID mice for 4 weeks. Muscle fiber size distribution
(e), fiber count (f), and fiber type (g) of GA muscle from CB17-SCID mice after 4-week treatment with 10 mg/kg of control antibody or REGN1033. Muscle
fiber type and number are representatives of five independent studies. h Isometric force as a function of stimulation frequency of TA muscle at the end
of 3 weeks of treatment with isotype control antibody or REGN1033. Peak tetanic force (i) and specific force (j) from the experiment shown in h. All
groups had 5–10 animals. Data are means ± SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001 isotype vs. control
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and prevented in the REGN1033 treatment group (11.8 %
increase above saline treated mice) (Fig. 5d). Specific force
remained unchanged in muscle from control antibody-
treated mice receiving saline or dexamethasone as well as
dexamethasone and REGN1033 (Fig. 5e).
REGN1033 prevents disuse muscle atrophy and improves
recovery time in hindlimb suspension
Next, we determined the ability of REGN1033 to prevent
muscle atrophy and improve recovery following an ex-
tended period of hindlimb suspension. When control anti-
body (25 mg/kg) was administered during hindlimb
suspension, mice lost −16.7 ± 1.4 % (P < 0.0001, n = 7-8) of
TA muscle mass and −20.4 ± 1.6 % (P < 0.0001, n = 7-8) of
GA muscle mass (Fig. 6a). Treatment with REGN1033
(25 mg/kg) during hindlimb suspension prevented the loss
of muscle mass by 65 % in TA and 57 % loss in GA muscle
(Fig. 6a).
To test the effects of REGN1033 during the recovery
phase from hindlimb suspension, we utilized 1 year-old
mice, since they show slower recovery in regaining muscle
mass than young mice. Seven days of hindlimb suspension
in these old mice decreased muscle mass by −12.7 ± 3.7 %
(P < 0.05, n = 5) in TA and −13.7 ± 4.9 % (P < 0.05, n = 5)
in GA muscle (Fig. 6b). Upon hindlimb suspension cessa-
tion, mice that received control antibody during the 7-day
recovery phase regained half of their muscle mass (Fig. 6b).
In contrast, the presence of REGN1033 (10 mg/kg) during
this phase significantly augmented recovery, resulting in
muscle weights higher than those of unperturbed mice
(Fig. 6b).
REGN1033 increases muscle mass and strength and
running endurance in aged-year-old mice
Decrease in muscle strength and function are considered
a consequence of age-related sarcopenia. As inhibition
Fig. 3 Myostatin, latent complex, and precursor forms bound by REGN1033 in vivo. a Antibody complexes present in serum samples from C17-SCID
mice that had received multiple REGN1033 or isotype-matched control antibody injections over 28 days were collected by immunoprecipitation, separated
by non-reducing SDS-PAGE, and immunoblotted with a myostatin antibody. The first lane contains conditioned medium from CHO cells transiently
transfected with myostatin precursor expression vector to serve as a positive control; two independent serum immunoprecipitations from control or
REGN1033-treated mice are shown. Arrows indicate mature myostatin homodimer, unprocessed precursor, and myostatin monomer (M). Asterisk
indicates myostatin form believed to be partially processed precursor. All samples were resolved on the same gel and appropriate lanes are juxtaposed
for clarity. b Duplicate samples as described in a were probed with a myostatin propeptide antibody. Arrow indicates cleaved prodomain which
co-precipitates in complex with mature myostatin, arrowhead indicates unprocessed precursor, and asterisks indicate partially processed precursor forms.
c Sera from WT and Mstn−/− mice was probed with the myostatin antibody to demonstrate specificity. Arrows indicate myostatin precursor and mature
myostatin homodimer, and the asterisk indicates partially processed precursor, all of which are absent in the Mstn−/− sample
Fig. 4 Gene expression in GA muscle from REGN1033 treated mice. Gene changes (twofold, p < 0.01) in GA muscle from CB17-SCID (a) and C57BL/6
(b) mice dosed at 10 mg/kg for 3 to 4 weeks. Results are expressed in reads per kilobase per million (RKPM). Data are means ± SEM of four mice
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of myostatin with REGN1033 could potentially be useful
for counteracting the progressive loss of muscle mass and
function in the aging population, we tested the efficacy of
REGN1033 in 24 month-old C57BL/6 mice. REGN1033
(10 mg/kg) induced a significant increase in TA and GA
muscle mass (Fig. 7a). No change in heart weights was ob-
served (data not shown). Importantly, TA muscles from
aged mice treated with REGN1033 showed a significant
increase in the maximum force generated (Fig. 7b, c). Spe-
cific muscle force remained unchanged between the treat-
ment groups (Fig. 7d). These data show that REGN1033
increases muscle mass and force in aged mice.
We next evaluated the effects of REGN1033 in a model
of muscle endurance, measuring muscle mass and exercise
performance in aged male C57BL/6 mice at 19 months of
age. A running exercise protocol was used during a 3-
week period during which mice received 10 mg/kg of
REGN1033 or control antibody. Two additional groups of
mice receiving REGN1033 or control antibody (10 mg/kg)
were used as sedentary controls. Figure 7e shows that ex-
ercise training did not increase muscle mass and that
REGN1033 induced comparable muscle hypertrophy over
controls in both sedentary animals (11.6 % increase over
controls) and in exercised animals (11.0 % increase over
Fig. 5 REGN1033 prevents muscle atrophy by immobilization and dexamethasone treatment. a GA muscle weights from mice in which the right
hindlimbs were immobilized for 14 days. REGN1033 or isotype control antibody was dosed during the 14-day immobilization period. Results are
expressed as the percent change compared to muscle weights of non-immobilized limbs. Statistical significance vs. non-immobilized control is indicated.
b TA and GA muscle weights from C57BL/6 mice implanted with osmotic pumps delivering saline or dexamethasone (Dex; 23 μg/day) and simultaneously
treated with REGN1033 or isotype control antibody (10 mg/kg) for 2 weeks. Results are presented as the percent change compared to muscle weights of
the saline pump control group. Statistical significance vs. saline control is indicated as asterisk, whereas significance vs. Dex plus isotype control is indicated
as number sign. c Isometric force as a function of stimulation frequency of TA muscle from mice implanted with osmotic pumps delivering saline or
dexamethasone (Dex) and treated with REGN1033 or isotype control antibody (10 mg/kg) for 2 weeks. Statistical significance vs. saline control is indicated
as asterisk, whereas significance vs. Dex plus isotype control is indicated as number sign. Similar to c but depicting peak tetanic force (d) or specific force
(e). All groups had 5–12 animals. Data are means ± SEM. *P < 0.05, **P < 0.01, ***P< 0.001, ****P< 0.0001 and ##P< 0.01, ###P< 0.001, ####P< 0.0001
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controls), indicating that exercise alone did not increase
muscle mass in aged mice and that exercise is not re-
quired for the ability of REGN1033 to induce hypertrophy.
In exercised aged mice, it appeared as though REGN1033
increased endurance, as indicated by strong trend toward
increased treadmill running time and distance when com-
pared with exercised control mice (Fig. 7f, g). These re-
sults suggest that REGN1033 can increase physical
performance outcomes above that achieved with exercise
training in aged mice.
Discussion
We report the development and characterization of
REGN1033, a fully human monoclonal antibody that has
high affinity and specificity to myostatin. In vivo,
REGN1033 (1) induced skeletal muscle hypertrophy and
increased muscle force in young and aged mice, (2) pre-
vented the loss of skeletal muscle mass in models of at-
rophy and accelerated the recovery of muscle mass from
pre-existing atrophy, and (3) improved physical perform-
ance outcomes in combination with treadmill exercise in
2-year-old mice. Our results indicate that specific block-
ade of myostatin with REGN1033 has the potential to
provide a safe and effective therapy for human diseases
that are associated with decreased skeletal muscle mass
and function in both young and elderly individuals.
It has previously been reported that administration of
myostatin-directed monoclonal antibodies in adult mice
increases muscle mass and strength and attenuates muscle
atrophy [20–25]. It is important to note that these anti-
bodies either blocked additional transforming growth fac-
tor beta (TGFβ) family members or their specificity was
not reported. While blockade of multiple TGFβ ligands
may provide a useful approach to maximize efficacy in
muscle wasting conditions, these ligands have a diverse
range of target tissues and biological roles, many of which
are not fully understood. Here, we report that REGN1033
inhibits myostatin with high affinity and specificity. In-
deed, REGN1033 does not bind or block GDF11, which is
more than 90 % identical to mature myostatin. The lack of
cross-reactivity to GDF11 is important, since data suggest
that GDF11 has beneficial effects in aged skeletal muscle
and reverses age-related cardiac hypertrophy [26, 27], so
that blockade of GDF11 would not be desirable. However,
these findings have recently been challenged and suggest
that GDF11 increases with age and inhibits muscle regen-
eration [28]. Few gene changes were observed in muscle
from REGN1033-treated mice. This emphasizes the spe-
cificity of REGN1033 for myostatin and that a specific
gene program is turned on to promote muscle growth.
Zmynd17 is the most downregulated gene in TA muscle
from both SCID and C57BL/6 mice. Based on these
findings, we generated Zmynd17-deficient mice. Com-
parison between Zmynd17 deficient and wild-type
Fig. 6 Effects of REGN1033 on muscle atrophy induced by hindlimb
unloading. a TA and GA muscle mass after treatment with REGN1033 or
an isotype control antibody during 7 days of hindlimb unloading (HLS).
One group of mice served as control to the HLS group and received
injections with the isotype control antibody. Weights were normalized
according to starting body weight, and data are expressed as percent
change from normalized non-hindlimb suspended control group.
Significance was calculated over normalized non-hindlimb suspended
isotype control group (asterisk) or over normalized hindlimb suspended
isotype control group (number sign). b Muscle weights at the end of
7 days of hindlimb unloading (HLS) or 7 days of HLS plus 7 days of
recovery (HLS + rec). Groups of mice were dosed with isotype control or
REGN1033 (10 mg/kg) during the 7-day recovery period. Changes
in muscle weights are depicted as the difference in muscle weights
compared to the no-hindlimb-suspended group. Statistical significance
was calculated vs. animals that were not-hindlimb-suspended (no HLS)
or against animals that were hindlimb-suspended for 7 days (7-day HLS).
All groups had four to six animals. Data are means ± SEM. *P < 0.05,
**P < 0.01, ****P < 0.0001 and ##P < 0.01, ###P < 0.001, ####P < 0.0001
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littermates did not reveal differences in body weight,
glucose homeostasis, as well as skeletal muscle mass
and function (data not shown). This suggests that down
regulation of Zmynd17 expression is a consequence ra-
ther than a cause of muscle growth in response to
REGN1033 administration.
REGN1033 displays the ability to recognize and bind
multiple circulating forms of myostatin including the la-
tent complex and unprocessed precursor. While release of
active myostatin from its inactive latent form is thought to
occur through BMP1-type proteolytic cleavage of its pro-
peptide [29], little is known about the in vivo regulation of
this activation step or the fraction of free bioactive myos-
tatin present in circulation. Thus, REGN1033 provides an
opportunity to limit the signaling potential of latent pools
of myostatin, independent of subsequent activation steps.
Administration of REGN1033 antibody at doses as low
as 2.5 mg/kg in mice increased muscle mass by 15–25 %,
with no significant effect on heart weight. Myostatin is
expressed in the adult heart at very low levels [4, 30]. The
increase in skeletal muscle mass is due to fiber hyper-
trophy without fiber hyperplasia or fiber-type switching
and results in higher muscle isometric force. The in-
crease in muscle mass is similar to that observed follow-
ing post-developmental [31] inactivation of myostatin
for 3–4 months [32] and slightly less than following fol-
listatin overexpression, which results in inactivation of
both myostatin and activin A [33]. Finally, in adult
myostatin null mice, the two- to threefold increase in
skeletal muscle mass results primarily from fiber hyper-
plasia and also from a 10–30 % increase in fiber hyper-
trophy [34–36]. These data suggest that in adult mice,
Fig. 7 Effects of REGN1033 on muscle mass and exercise performance in aged mice. a TA and GA muscle weights of 24-month-old mice receiving
REGN1033 or isotype control antibody treatment (10 mg/kg) for 3 weeks. Muscle weights were normalized by starting body weights and expressed as
percent changes from isotype control. b Isometric force as a function of stimulation frequency of TA muscle at the end of 3 weeks of treatment with
isotype control antibody or REGN1033. Same as in b but depicting peak tetanic TA muscle force (c) or specific force (d). TA (e) and GA (f) muscle
weights at the end of 3 weeks of treatment with REGN1033 or isotype control antibody (10 mg/kg) from 19-month-old C57BL/ mice either left
sedentary or during a three week exercise regimen. Muscle weights were normalized by starting body weights and expressed as percent changes from
isotype control. g, h Treadmill exhaustion and maximal running capacity tests measured in the mice described in e, f. All groups had six to eight animals.
Data are means ± SEM. *P< 0.05, **P< 0.01, ****P< 0.0001 vs. sedentary isotype control and ##P < 0.01 vs. sedentary REGN1033
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REGN1033 fully blocks myostatin action in vivo and
causes a maximal increase in muscle hypertrophy. The
data also imply that the primary role of myostatin during
development is to regulate satellite cell activation and fu-
sion to myofibers and that this mechanism does not seem
to play a significant role for changes in skeletal muscle
mass following myostatin inhibition in the adult mouse in
physiological settings [31, 37]. In addition to inducing
hypertrophy in unperturbed animals, REGN1033 also pre-
vented the loss of skeletal muscle mass in models of
muscle atrophy, such as hindlimb suspension, casting
immobilization, and dexamethasone treatment. Import-
antly, REGN1033 also prevented the loss of muscle
strength in atrophy settings and accelerated recovery from
pre-existing atrophy.
There is a large unmet medical need for treatment op-
tions for alleviation of muscle atrophy in elderly patients
recovering from orthopedic disuse following joint re-
placement or repair surgery and in those patients im-
pacted by the frailty and morbidity associated with
generalized sarcopenia. We show that antagonism of
myostatin with REGN1033 not only increases muscle
mass and strength in aged-month-old mice similar to
that observed in young mice but also improves exercise
endurance as measured by the time and distance that
mice ran on a treadmill before exhaustion.
Conclusions
In summary, our data provides further support for the
notion that specific antagonism of myostatin can en-
hance skeletal muscle mass and function in normal mice
and multiple settings of atrophy. Of interest, administra-
tion of REGN1033 can also act to speed up muscle re-
covery and has the potential to alleviate muscle frailty in
aged populations.
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